Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

In women with endometriosis, however, the endometrial tissue often exhibits ‘progesterone resistance.’ This means the cells do not respond effectively to progesterone, disrupting the natural ...